(+) -JNJ-A07
(+) -JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+) -JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+) -JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models[1].
Product Specifications
CAS Number
[2135640-93-4]
UNSPSC
12352005
Target
Dengue Virus; Flavivirus; Virus Protease
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/plus-jnj-a07.html
Concentration
10mM
Purity
98.46
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC(CCCOC1=CC(OC)=CC(NC(C2=CC=C(C=C2)Cl)C(N3C4=CC(OC(F)(F)F)=CC=C4CC3)=O)=C1)=O.[Rotation(+)]
Molecular Formula
C28H26ClF3N2O6
Molecular Weight
578.96
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
B4GALNT1 (Beta-1, 4-N-Acetyl-Galactosaminyl Transferase 1, GALGT, GALNACT) (FITC)
